September 2025
1. ABUSHAKRA S, Power A, Watson D, Porsteinsson A, et al
   Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEepsilon4/epsilon4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial.
   Drugs. 2025 Sep 28. doi: 10.1007/s40265-025-02250.
   

   >> Share

   
   
2. SMOLLER C, Schiller E, Yamashita K, Silverglate BD, et al
   Current and Emerging Pharmacological Approaches to Agitation in Alzheimer's Disease: A Narrative Review of New and Repurposed Therapies.
   Drugs. 2025 Sep 6. doi: 10.1007/s40265-025-02227.
   

   >> Share

   
   January 2025
3. SYED YY
   Xanomeline/Trospium Chloride: First Approval.
   Drugs. 2025;85:103-109.
   

   >> Share

   
   October 2024
4. CARPI M, Mercuri NB, Liguori C
   Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer's Disease and Associated Sleep Disorders.
   Drugs. 2024 Oct 4. doi: 10.1007/s40265-024-02096.
   

   >> Share

   
   
5. KANG C
   Donanemab: First Approval.
   Drugs. 2024;84:1313-1318.
   

   >> Share

   
   June 2024
6. HEY JA, Yu JY, Abushakra S, Schaefer JF, et al
   Analysis of Cerebrospinal Fluid, Plasma beta-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology Model.
   Drugs. 2024 Jun 20. doi: 10.1007/s40265-024-02068.
   

   >> Share

   
   
7. HEY JA, Abushakra S, Blennow K, Reiman EM, et al
   Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease.
   Drugs. 2024 Jun 20. doi: 10.1007/s40265-024-02067.
   

   >> Share

   
   September 2023
8. CUMMINGS JL, Osse AML, Kinney JW
   Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification.
   Drugs. 2023 Sep 20. doi: 10.1007/s40265-023-01938.
   

   >> Share

   
   April 2023
9. CUMMINGS J
   Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics.
   Drugs. 2023 Apr 15. doi: 10.1007/s40265-023-01858.
   

   >> Share

   
   March 2023
10. HOY SM
    Lecanemab: First Approval.
    Drugs. 2023;83:359-365.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share